Last reviewed · How we verify
L-ASP
L-ASP (L-asparaginase) depletes the amino acid asparagine in leukemic cells, which cannot synthesize their own asparagine and thus undergo apoptosis.
L-ASP (L-asparaginase) depletes the amino acid asparagine in leukemic cells, which cannot synthesize their own asparagine and thus undergo apoptosis. Used for Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia (AML).
At a glance
| Generic name | L-ASP |
|---|---|
| Sponsor | First Affiliated Hospital of Zhejiang University |
| Drug class | Enzyme (asparagine depleting agent) |
| Target | Asparagine |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
L-asparaginase is an enzyme that catalyzes the hydrolysis of asparagine to aspartic acid and ammonia. Acute lymphoblastic leukemia (ALL) cells are dependent on exogenous asparagine for protein synthesis and survival, whereas normal cells can synthesize asparagine endogenously. By depleting circulating asparagine, the drug selectively starves leukemic cells of this essential amino acid, leading to cell death.
Approved indications
- Acute lymphoblastic leukemia (ALL)
- Acute myeloid leukemia (AML)
Common side effects
- Hypersensitivity reactions
- Pancreatitis
- Hepatotoxicity
- Coagulopathy
- Nausea and vomiting
- Hyperglycemia
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery (PHASE1)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Neurobiology of Suicide (PHASE2)
- Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder (PHASE2)
- Pharmacokinetics of Zelquistinel in Fasted or Fed State (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-ASP CI brief — competitive landscape report
- L-ASP updates RSS · CI watch RSS
- First Affiliated Hospital of Zhejiang University portfolio CI